Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Dec 12, 2022
Trial Information
Current as of January 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified. Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection.
Investigators will collect peripheral blood at 1 month, 2 month, 3 month, and 6 month after HSCT from the participated patients, and dynamically monitor the CMV-specific T and NK cellular immune reconstitution.
...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Be receiving a first allogeneic HSCT.
- • Is male or female, from 14 years to any years of age inclusive.
- • The participant (or legally acceptable representative) agree for cellular immune investigation and has provided documented informed consent/assent for the study.
- Exclusion Criteria:
- • Received a previous allogeneic HSCT (Note: Receipt of a previous autologous HSCT is acceptable).
- • Has a history of CMV end-organ disease within 6 months prior to allocation.
- • Has severe organ (hepatic , renal, cardical) insufficiency within 5 days prior to allocation.
- • Any rapidly-progressing disease or immediately life-threatening illness.
About Peking University People's Hospital
Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Beijing, Beijing, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials